FTC Launches ‘Colonoscopy’ Into PBM Practices, Including Focus On Consumer Costs, Access
Executive Summary
Study will examine how the six largest pharmacy benefit managers in the US handle 10 disease categories. Federal Trade Commissioners unanimously support inquiry after its scope was broadened from an earlier version that drew objections from Republicans.
You may also be interested in...
Rebates In Part D: HHS Argues Scrutiny Of Impact On Formularies, Beneficiaries Not Needed Now
New GAO recommendations springing from recent Medicare Part D cost and access trends related to rebates may not be relevant going forward because the IRA price negotiation program and benefit redesign will significantly change the landscape, HHS says.
FTC Downplaying Previous Concerns With Mandatory PBM Transparency
The commission aims to undercut large PBMs' use of its previously stated concerns as support for their lobbying against state and federal industry reforms, but the PBM trade association remains undeterred by the action.
FTC’s Khan Addresses PBMs, Amgen-Horizon Merger, At Contentious Congressional Hearing
Republican members of the House Judiciary Committee question FTC policies under Khan’s leadership, including its challenge of the Amgen-Horizon and Illumina-Grail mergers, as well as a proposal to require more information in pre-notification submissions. ‘You’re a bully,’ Representative Issa tells her.